Maze Therapeutics, Inc. MAZE
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.59% | -335.93% | -- | -- | -- |
| Total Depreciation and Amortization | -32.59% | -28.64% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.50% | 27.03% | -- | -- | -- |
| Change in Net Operating Assets | 34.47% | -667.09% | -- | -- | -- |
| Cash from Operations | -1.25% | -273.93% | -- | -- | -- |
| Capital Expenditure | 78.43% | 49.61% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -20,792.93% | -13,986.38% | -- | -- | -- |
| Total Debt Issued | -- | 15,112.74% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 128.44% | 20.46% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 65.53% | 2.27% | -- | -- | -- |
| Cash from Financing | 71.92% | -2.72% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -169.18% | -136.17% | -- | -- | -- |